Post-Traumatic Thromboembolism. Pathogenesis, Diagnosis and Prevention M. Margaret Knudson, MD

Similar documents
VTE in the Trauma Population

The association between injury and venous thromboembolic

THROMBOEMBOLIC EVENTS AFTER IVC FILTER PLACEMENT IN TRAUMA PATIENTS. Lidie Lajoie, MD SUNY Downstate Department of Surgery December 20, 2012

CURRENT & FUTURE THERAPEUTIC MANAGEMENT OF VENOUS THROMBOEMBOLISM. Gordon Lowe Professor of Vascular Medicine University of Glasgow

CHAPTER 2 VENOUS THROMBOEMBOLISM

PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM

INFERIOR VENA CAVA FILTERS QUIZ 10 QUESTIONS MAY 5, 2014

Low Molecular Weight Heparin for Prevention and Treatment of Venous Thromboembolic Disorders

DVT Pathophysiology and Prophylaxis in Medically Hospitalized Patients. David Liff MD Oklahoma Heart Institute Vascular Center

PE and DVT. Dr Anzo William Adiga WatsApp or Call Medical Officer/RHEMA MEDICAL GROUP

Inferior Venacaval Filters Valuable vs. Dangerous Valuable Annie Kulungowski. Department of Surgery Grand Rounds March 24, 2008

Venous thrombosis is common and often occurs spontaneously, but it also frequently accompanies medical and surgical conditions, both in the community

Slide 1. Slide 2. Slide 3. Outline of This Presentation

Misunderstandings of Venous thromboembolism prophylaxis

Risk factors for DVT. Venous thrombosis & pulmonary embolism. Anticoagulation (cont d) Diagnosis 1/5/2018. Ahmed Mahmoud, MD

Venous thrombosis & pulmonary embolism. Ahmed Mahmoud, MD

DENOMINATOR: All surgical patients aged 18 years and older undergoing procedures for which VTE prophylaxis is indicated in all patients

Prevention of Venous Thromboembolism in High-Risk Patients

Cost-effective prevention of pulmonary embolus in high-risk trauma patients Brasel K J, Borgstrom D C, Weigelt J A

CPT only copyright 2014 American Medical Association. All rights reserved. 12/23/2014 Page 66 of 593

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

Pulmonary Thromboembolism

Venous Thromboembolism. Prevention

Mabel Labrada, MD Miami VA Medical Center

Disclosures. DVT: Diagnosis and Treatment. Questions To Ask. Dr. Susanna Shin - DVT: Diagnosis and Treatment. Acute Venous Thromboembolism (VTE) None

Venous Thrombo-Embolism. John de Vos Consultant Haematologist RSCH

PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM

Anticoagulation for prevention of venous thromboembolism

Venous Thromboembolism Prophylaxis

Dr. Rami M. Adil Al-Hayali Assistant Professor in Medicine

Thromboembolic events (TEs), such as deep vein

CANCER ASSOCIATED THROMBOSIS. Pankaj Handa Department of General Medicine Tan Tock Seng Hospital

Venous Thromboembolism Prophylaxis: Checked!

DVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE)

Inferior Vena Cava Filters

The Johns Hopkins Hospital Patient Information. How Do I Prevent Blood Clots? Venous Thromboembolism (VTE) Deep Vein Thrombosis (DVT)

Predicting Venous Thromboembolic Complications following Neurosurgical Procedures

Epidemiology of Thrombosis in Patients with Malignancy. Cancer and Venous Thromboembolism. Chew HK, Arch Int Med, Feb Blom et al, JAMA, Feb 2005

CADTH Rapid Response Report: ASA for Venous Thromboembolism Prophylaxis: Evidence for Clinical Benefit and Harm

DEEP VEIN THROMBOSIS (DVT): TREATMENT

Medical Patients: A Population at Risk

Trauma Measure #3 Venous Thromboembolism (VTE) Prophylaxis in Abdominal Trauma. National Quality Strategy (NQS) Domain: Patient Safety

Pulmonary embolism (PE) has often been considered a

Clinical Guide - Inferior Vena Cava Filters (Reviewed 2006)

Prevention and management of deep venous thrombosis (DVT) John Fletcher Wound Care Association of New South Wales

Deep vein thrombosis and its prevention in critically ill adults Attia J, Ray J G, Cook D J, Douketis J, Ginsberg J S, Geerts W H

Pulmonary Embolism. Pulmonary Embolism. Pulmonary Embolism. PE - Clinical

EAST MULTICENTER STUDY DATA DICTIONARY

VTE Management in Surgical Patients: Optimizing Prophylaxis Strategies

Inferior Vena Cava Filter for DVT

Disclosures. What is a Specialty Vein Clinic? Prevalence of Venous Disease. Management of Venous Disease: an evidence based approach.

INDICATIONS FOR THROMBO-PROPHYLAXIS AND WHEN TO STOP ANTICOAGULATION BEFORE ELECTIVE SURGERY

A national survey of thromboprophylaxis strategies in high risk trauma patients.

Inferior Vena Cava Filters- Are they Followed up? By Dr Nathalie van Havre Dr Chamica Wijesinghe Dr Kieren Brown

Thromboembolic prophylaxis

Top 5 (or so) Hematology Consults. Tom DeLoughery, MD FACP FAWM. Oregon Health and Sciences University DISCLOSURE

Challenges in Anticoagulation and Thromboembolism

DEEP VENOUS THROMBOSIS A PRACTICAL APPROACH TO IMPROVING CLINICAL OUTCOMES

Not all Leg DVT s are the Same: Which Patients Benefit from Interventional Therapy? Case 1:

Deep Venous Thrombosis, Pulmonary Embolus and IVC Filters. Michael Meuse, M.D. Vascular and Interventional Radiology

Venous thromboembolic diseases: diagnosis, management and thrombophilia testing (2012) NICE guideline CG144

Clinical Implications of the Impact of Serum Tissue Factor Levels after Trauma

Prevention of Venous Thromboembolism

THROMBOSIS RISK FACTOR ASSESSMENT

The Eastern Association for the Surgery of Trauma

Diagnostic Algorithms in VTE

Clinical Practice Management Guideline for Venous Thromboembolism Prevention

Surgical approach for DVT. Division of Vascular Surgery Department of Surgery Seoul National University College of Medicine

Pharmacy Prior Authorization

Deep Vein Thrombosis and Pulmonary Embolism in the Perioperative Patient

ARTEMIS. ARixtra (fondaparinux) for ThromboEmbolism prevention in. a Medical Indications Study. NV Organon Protocol 63129

Objectives. Venous Thromboembolism (VTE) Prophylaxis. Case VTE WHY DO IT? Question: Who Is At Risk?

Implications from the ACCP 2012 Consensus Guidelines for the Management of Thrombosis: a case based approach

I am NOT: Disclosures. The Problem of the Con-Position Non Thinking! Against New Ideas. Against New Therapies. Against Endovascular Therapies

Dr. Riaz JanMohamed Consultant Haematologist The Hillingdon Hospital Foundation Trust

Early Ambulation Reduces the Risk of Venous Thromboembolism After Total Knee Replacement. Marilyn Szekendi, PhD, RN

VENOUS THROMBOEMBOLISM: DURATION OF TREATMENT

Is Oral Rivaroxaban Safe and Effective in the Treatment of Patients with Symptomatic DVT?

Single Center 4 year series of 114 consecutive patients treated for massive and submassive PE. Mark Goodwin, MD

IVC Filters: For Whom, Why and When?

Tarkten A Pharr, MD, FACS 04/26/2018. VTE Prevention Strategies: Is a One Size Fits all Approach Correct?

Fatal P.E. Historic 1-2% Current %

Jessica Bryan, Natalia Evans, Karlyn Henderson, & Whitney Parks

Venous Thromboembolic Disease Update

Handbook for Venous Thromboembolism

Getting Started Kit VENOUS THROMBOEMBOLISM PREVENTION. Section 2: Evidence-Based Appropriate VTE Prophylaxis

Venous thrombotic, thromboembolic, and mechanical complications after retrievable inferior vena cava filters for major trauma

IVC Filters: Rate of Insertion, Indications, Effects on Prognosis, Evidence Basis for Current Practices. Paul D. Stein, MD

What s New in DVT & PE

Perioperative VTE prophylaxis (ACCP 9 th edition Guidelines) Gamal Marey SUNY Downstate Medical Center 10/16/2014

PULMONARY EMBOLISM (PE): DIAGNOSIS AND TREATMENT

VENOUS THROMBOEMBOLISM (VTE) PREVENTION MEDICAL PROVIDER EDUCATION JUNE 2017

Symptomatic Venous Thromboembolism after Total Hip/Knee Replacement: A Population-based Taiwan Study

Diagnosis and Treatment of Deep Venous Thrombosis and Pulmonary Embolism

Deep Vein Thrombosis and Pulmonary Embolism: Patient Information

OBSTETRIC ADMISSION ORDERS 1 of 4

Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC

Perioperative Management of the Anticoagulated Patient

Venous Thromboembolism National Hospital Inpatient Quality Measures

Transcription:

Post-Traumatic Thromboembolism Pathogenesis, Diagnosis and Prevention M. Margaret Knudson, MD

Historical Perspectives A study of protocols of 9,882 postmortem exams including death from injury in the traumatic group embolisms were found in 61 cases(3.8%) and in the non-traumatic group in 222 cases (2.6%). Statistically, this appears to be a significant difference. J.S. McCartney, 1934

Historical Perspectives 124 trauma patients: venograms Fracture patients: 35% venous thrombosis Thrombus found within 24 hours of injury Both injured/uninjured extremity 2/3rds with DVT-asymptomatic Freeark et al, 1967

Pathophysiology: : VTE Direct injury to endothelium As surgical incision is made: veins remote from site dilate Stasis/inflammation/thrombosis

Knudson s s Trauma Triad VENOUS TRAUMA FRACTURES ENDOTHELIAL DAMAGE STASIS PARALYSIS IMMOBILIZATION HYPERCOAGULABILITY MULTIPLE TRANSFUSIONS SEVERE INJURIES

INCIDENCE: OCCULT DVT 349 injured patients: screening venography* None receiving prophylaxis Proximal DVT rate: 18% PE rate: 2% (43% mortality!!) *Geerts et al, NEJM 1994

Incidence of Occult PE after Trauma 90 consecutive patients; ISS> 9 Asymptomatic; no DVT Chest CT: between 3-7 days 22 had clot on CT; 4 were major! 30% were receiving prophylaxis Schultz et al J Trauma 2004

The Goddess of Ultrasound

Detection: DVT Silent DVT: 10-18% of high-risk patients Surveillance Scanning: Cost-effective in trauma patients: 14 days* 30% of DVT: upper extremity (missed by lower extremity venography) Supplement to inadequate prophylaxis * Brasel, J Trauma 1997

Detection of PE CT angiography: most commonly used Low sensitivity: 50% for central PE * 28% for peripheral PE Multi-slice CT+ neg. D-dimer + neg. duplex: highest sensitivity** 1-2% of trauma patients: FATAL PE *Velmahos J Trauma, 2004; **Perrier NEJM 2005

Initial Study: Knudson et al Study #1: 113 patients at Stanford Serial scanned: duplex ultrasound All patients received prophylaxis: Overall VTE rate: 10% PE rate: 6%! no PE deaths LDH - same as SCD: effective?

Knudson: Study #1 Results J Trauma, 1992 50 40 30 20 10 0 age Days Imm # RBCs PTT sec. no VTE VTE

Knudson: Study #2 J Trauma, 1994 251 randomized patients: serial CFD LDH vs. SCD vs. Controls 6%: DVT; 2 PE: 50% mortality SCD only effective in TBI patients LDH: no better than nothing

Low Molecular Weight Heparin Short heparin chains High affinity for antithrombin More predictable anticoagulant activity - longer 1/2 life - bioavailability - less bleeding

LMWH in Trauma Patients Canadian study: LDUH vs LMWH Venography DVT rate - 15% vs 6% -Geerts, NEJW, 1996 US study: Mechanical vs LMWH Duplex DVT rate - 2.5% vs 0.8% -Knudson, J Trauma 1996

Prophylactic Vena Cava Filters? Problems: - Recurrent PE: 3% -No protection against DVT - 10%: caval thrombosis - permanence: leg edema - migration/ivc perforation - timing: 6% PE within 24 hours

Retrievable Filters: NOT May be retrieved within 5 days May be left in place: 30 days? Solution for high risk patients? Leads to 3-fold increase use AAST study: >400 patients Only 22% were retrieved! $100,000/ PE prevented Antevil J Trauma 2006 Karmy-Jones J Trauma 2007

THROMBOEMBOLISM AFTER TRAUMA AN ANALYSIS OF 1602 EPISODES FROM THE ACS NATIONAL TRAUMA DATA BANK M. Margaret Knudson MD Danagra G. Ikossi MD Linda Khaw BA Diane Morabito RN, MPH Larisa S. Speetzen BA The University of California, San Francisco

NATIONAL TRAUMA DATA BANK Largest trauma database available Sponsored by the ACS/COT Data: 2 million patients De-identified data for research SOURCE: CLINICAL BENCHMARKING

VTE RISK FACTOR ANALYSIS Hypotheses: Clinical incidence of VTE - relatively low Patients who would benefit from VTE prophylaxis could be clearly identified

METHODS Data source: NTDB (1994-2001) Data analysis: - Demographics - Nature/severity of injuries - Complications/outcomes Survey: participating trauma centers - VTE risk factors/protocols

RESULTS 450,375 patients included 84% blunt injuries 31% ISS>10 998 pts: DVT (0.36%) 522 pts: PE (0.13%) 82 pts: both DVT/PE PE mortality: 18.7%

RISK FACTOR ANALYSIS Risk Factor * Shock on admission (BP < 90 mhg) Age > 40 yrs. Head injury (AIS > 3) Pelvic fracture Lower extremity fracture Spinal cord injury with paralysis * Greenfield 1997, 2000; Knudson 1994, 1996 Odds Ratio 1.95 2.29 2.59 2.93 3.16 3.39 p <.0001 for all factors

RISK FACTOR ANALYSIS (CONT ) Risk Factor Major surgical procedure Venous injury Ventilator days > 3 Odds Ratio 4.32 7.93 10.62 p <.0001 for all factors

MULTIVARIATE ANALYSIS Risk Factor Head injury (AIS 3) Major operative procedure Lower extremity fracture (AIS 3) Age 40 years Venous injury Ventilator days > 3 Odds Ratio 1.24 1.53 1.92 2.01 3.56 8.08 p 0.0125 for all factors

VENA CAVA FILTERS Procedure code: IVC plication 3,883 patients 86%: prophylaxis (no VTE) PE rate in filter group: 4.7% 410 patients: no risk factors Permanent IVC filters

SURVEY RESULTS Majority: identified risk factors for VTE 50%: VTE protocol in place Preferred prophylaxis: LMWH 16%: VCF-heparin contraindicated

CONCLUSIONS Clinically significant VTE rates: low 90% VTE pts. have at least 1 risk factor VTE risk- varies with each factor Role of IVC filters: re-examined

STUDY LIMITATIONS Level II recommendations Quality of data: variable Type II error: spinal cord injuries Risk factors: missed 10% pts with VTE Limited data: pre-existing risk factors Unable to link prophylaxis with VTE

Spinal cord injuries Highest risk trauma patients DVT rates: 80% PE rates: 5% PE-most common cause of death

PROPOSED ALGORITHM Injured Patient High Risk Factor (OR for VTE = 2-3) 2 Age 40 Pelvic fx Lower extremity fx Shock Spinal cord injury Head trauma (AIS 3) VERY High Risk Factor (OR for VTE = 4-10) 4 Major operative procedure Venous injury Ventilator days > 3 2 or more high risk factors Contraindication for heparin? Contraindication for heparin? No LMWH* *Prophylactic dose Yes Mechanical compression No LMWH* and mechanical compression Yes Mechanical compression and serial CFD OR temporary IVC filter

DVT PROPHYLAXIS: PATIENT CHARGES- SFGH Avg. 2 Week Charge Sequential Compression Devices $679 -stockings, sleeves, pump LMWH $3,220-30mg/twice daily IVC Tulip (insertion/removal) $10,400* -filter and procedure charges Serial CFD Scanning $1,700* -scan/tech charges *Does not include professional fees

Practice Patterns VTE Prophylaxis in Trauma 315 patients: 11% VTE Early prophylaxis: 4% risk Prophylaxis after 4 days: 3 times greater!

Fondaparinux Synthetic pentasaccharide; non-heparin Selective AT binding: neutralizes Xa 300 times innate AT III activity

FONDAPARINUX More effective than enoxaparin: ortho Less bleeding/lower mortality: acute MI Once daily dosing No heparin; NO HIT Turpie NEJM 2001; Yusuf NEJM 2006

Fondaparinux for the Prevention of Venous Thromboembolism in High-Risk Trauma Patients J.P. Lu, MD U. Of California, San Francisco

Study Objectives To evaluate the efficacy and safety of fondaparinux for DVT prophylaxis in trauma patients To implement a VTE prevention protocol based on stratified risk factors To measure Fondaparinux anti Xa activity in trauma patients

Hypotheses VTE rate would be less than 5% in highrisk trauma patients with Fondaparinux Fondaparinux: no increased bleeding risk Anti-Xa activity would be therapeutic

Methods Subjects: consecutive admissions-6 months Inclusion criteria: Age >=18 Risk factor for VTE Anticipated hospital stay >= 5 days Exclusion criteria: Prisoners Pregnant women

Risk assessment INJURED PATIENT High Risk Factors (Odds ratio for VTE = 2 3) Age 40 Pelvic fx Lower extremity fx Shock Spinal cord injury Head Injury (Ais 3) Very High Risk Factors (Odds ratio for VTE = 4-10) Major operative procedure Venous injury Ventilator days > 3 2 or more high risk factors Does the patient have contraindication for anticoagulation? Does the patient have contraindication for anticoagulation? Yes No No Yes SCDs Serial ultrasound FND* Serial ultrasound Anti Xa FND* SCDs Serial ultrasound Anti Xa SCDs Serial ultrasound AND / OR Temporary IVC filter * Fondaparinux 2.5 mg sq

Methods Study period: 1-21 days Ultrasound surveillance on admission and then weekly Fondaparinux for DVT prophylaxis if patient had no contraindication; goal: <36hr Anti Xaactivity measured at third or fourth dose

Results: demographics Patients who received fondaparinux, n = 81 Age (yrs) Male sex 43.1 (+/- 19.3) 60 (74%) Blunt Injury 51 (63%) Mean ISS 18 (+/- 10.1)

Results: incidence of DVT 35 33.3 30 25 % 20 15 10 5 0 2.5 fondaparinux No fondaparinux n = 81 n = 6

Results: adverse events 13 (16%) had decrease in hematocrit No transfusions related to the drug No other major AEs identified

Results: anti Xa activity 0.4 mg/l 0.35 0.3 0.25 0.2 0.15 0.1 0.05 0 0.05 Trough 0.3 Peak

Summary Fondaparinux: safe and effective in trauma VTE protocol prospectively applied: successfully identified patients at risk Further multi-center studies are warranted

Factor VIIa: : A New Threat? Empiric administration to bleeding patients Produces hypercoagulable state early Late risk of thromboembolism??? Early data: small but not significant risk

Protein C: The Unifying Theory Trauma patients with shock Hypocoagulable state Protein C gets activated: depleted Later become hypercoagulable Low protein C: develop VTE Brohi/Cohen: Annals of Surgery 2006

DVT/PE Rate In Combat Injuries? Combination of very severe injuries Burns/Blasts/Fractures Prolonged immobilization Prolonged air travel>5,000 miles

Civilian vs Combat Burn Patients Retrospective review: 1107 patients Evacuated soldiers: younger, higher ISS Higher incidence of inhalation injuries Clinical incidence of VTE: 0.99% overall 1.31% in soldiers vs. 0.83% in civilians Chang et al 2007

Military experience: rfvii and DVT 615 patients: JTTR Retrospective review-clinical incidence Overall DVT rate: 7.5%; PE rate 3.8% Massive Transfusions: 13% Massive transfusions and rfvii: 18% Prospective study needed Have Sonosite will scan!!!

A Great Privilege!